Sigilon Therapeutics gets its name from the Spanish word “sigilo,” meaning stealth. The company’s mission is to develop therapies that can accomplish more by being less visible to the body’s immune system.
Participant Profile: Sigilon Therapeutics
Pioneering technologies that harness the total power of cell therapeutics.
Enter your email address to follow The Hive and get the latest updates on participants and milestones – followed by the email address submission box.
Initial therapeutic areas of interest include diabetes and blood disorders
While Sigilon is confident its therapy could help patients with a variety of diseases that require chronic dosing of a biologic, the company has started by focusing on areas that will provide the most significant benefits for patients balanced with the shortest path to approval. These initial target
areas include diabetes, blood disorders and lysosomal storage disorders.
Meet the team
Lauren Barney, PhD
Scientist
Richard Heidebrecht, Jr. PhD
Director of Chemistry Research
Guillaume Carmona, PhD
Senior Scientist
Janet Huang
In Vivo Biology Lead
Quotes
"The Hive gives me access to current literature related to biomaterials and cell therapy, which is necessary for effectively designing compelling and intelligent experiments. Without this resource, I’d be missing critical scientific and clinical information, ultimately resulting in inefficient and poorly designed work." Lauren Barney, Scientist
"The Hive program allows us to move at a fast past; so much information in one place, allowing our scientists more time to concentrate on their work in the lab." Richard Heidebrecht, Jr., Director of Chemistry Research
"With its wealth of tools, information and its user-friendly platform, The Hive is an invaluable resource for any biotech company. The Hive is helping us in our drug research and development programs and informed decision-making." Dr. Guillaume Carmona, Senior Scientist
"With so much work ahead of us, the Hive provides a tool that is invaluable." Janet Huang, In Vivo Biology Lead
Learn more about Elsevier's R&D solutions for drug discovery
and development utilized by Sigilon Therapeutics:
Reaxys
Improve R&D productivity with a chemistry research solution that delivers experimental facts on chemical structures, properties, reactions and procedures.
Learn more about Reaxys
Reaxys Medicinal Chemistry
Empower hit identification and lead optimization with normalized compound–target affinity data and comprehensive pharmacokinetic, efficacy, toxicity, safety and metabolic profiles.
Learn more about Reaxys Medicinal Chemistry
Embase
Increase the discovery of biomedical evidence to support critical life sciences functions, with access to the world's most comprehensive biomedical literature database.
Learn more about Embase
PharmaPendium
Enable better informed preclinical drug safety decisions with comprehensive, fully searchable FDA/EMA drug approval documents and comparative extracted drug safety data.
Learn more PharmaPendium
ScienceDirect
Enable researchers to more effectively and efficiently search authoritative, full-text scientific, technical and health content through the use of smart, intuitive functionality.
Learn more about ScienceDirect
Pathway Studio
Enable better understanding of biological processes underlying disease progression and treatment response, with a solution that helps researchers interpret experimental data from scientific literature.
Learn more about Pathway Studio
Scopus
Help researchers discover trends, partners and experts with the world’s largest abstract & citation database of peer-reviewed literature, including tools to track, analyze and visualize research.
Learn more about Scopus